J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

The lawsuits claim that Moderna used and profited from crucial mRNA technology in its COVID-19 vaccine Spikevax and ...

Artificial intelligence won’t replace people in biopharma, but it is infiltrating every step of drug development, including ...

The clinical hold affects Novavax’s COVID-flu combo and standalone flu vaccines, which were on the cusp of Phase III testing.

Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back from the infectious diseases market.